abc biopply webinar: A Novel 3D High Throughput Co-culture System for Multiple Myeloma

In this interesting webinar, Dr Johannes Waldschmidt from the university of Freiburg, Germany, has recently presented his work published last November in the Journal of Cancer Research and Clinical Oncology: Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma, Johannes M. Waldschmidt et al., JCRCO, November 2021.
In this study, the authors showed that the native micro environment generated in the 3D CoSeedis™ preclinical model not only helps to aggregate and propagate multiple myeloma (MM) cells ex vivo but consequently also leads to a much more accurate drug response outperforming alternative 3D technologies or 2D approaches. Moreover, the observed drug response to two classical compounds in MM treatment was a lot closer to the effects observed in patients and entirely opposite to the triggered behavior of cells in 2D.
“From a clinical viewpoint, this model may improve our ability to better predict later clinical success of preclinically active compounds to reduce time and financial expenses of drug discovery for MM at the earliest stage possible.”

J. M. Waldschmidt et al., JCRCO,
For the webinar, co-author, Dr Andreas Thomsen (university of Freiburg, Germany) introduced the topic by describing the 3D CoSeedis™ 3D cell culture platform in some detail. He also emphasized the importance of having a reliable and physiologically accurate test system available for preclinical studies in order to reduce failure rates in later clinical studies.
Watch Webinar
In addition, the webinar presents abc biopply’s service and assay portfolio and demonstrates how it can help design the most appropriate preclinical disease model for a given compound test.
The webinar was organized and moderated by the American Physiological Society, APS,  in collaboration with abc biopply and our American partner, nanoscaleLABS. The event was recorded and is made available on our website.

Are you interested to get to know more on abc biopply’s preclinical disease models or would you like to get further information on our assays and services? I am looking forward to answering your call.

   Best regards

   Marco Leu, PhD
   abc biopply ag

   Direct Email / Phone +41 (0)79 834 95 56


Back to overview

Contact us